Lung Cancer : Targets and Therapy
Overview
Lung Cancer : Targets and Therapy is a scientific journal, published by Dove Medical Press since 2010 in English. The journal's country of origin is New Zealand.
Details
Details
Abbr.
Lung Cancer (Auckl)
Publisher
Dove Medical Press
Start
2010
End
Continuing
Frequency
Irregular
e-ISSN
1179-2728
Country
New Zealand
Language
English
Metrics
Metrics
h-index / Ranks: 10997
27
SJR / Ranks: 3936
979
CiteScore / Ranks: 2355
7.80
Recent Articles
1.
Arter Z, Shieh K, Nagasaka M, Ou S
Lung Cancer (Auckl)
. 2025 Feb;
16:1-9.
PMID: 39995769
Background: mutations are generally divided into three classes based on the different altered mechanism of activation. Methods: We queried the public AACR GENIE database (version 13.1), which includes tumor mutation...
2.
Canale M, Urbini M, Petracci E, Angeli D, Tedaldi G, Priano I, et al.
Lung Cancer (Auckl)
. 2025 Feb;
16:11-23.
PMID: 39995768
Objective: Extensive stage Small-Cell Lung Cancer (ES-SCLC) is the most lethal lung cancer, and the addition of immunotherapy conferred a slight survival benefit for patients. Extensive molecular profiling of patients...
3.
Lee A, Nagasaka M
Lung Cancer (Auckl)
. 2024 Dec;
15:169-176.
PMID: 39717628
Mutations in KRAS G12C are among the more common oncogenic driver mutations in non-small cell lung cancer (NSCLC). In December 2022, the US Food and Drug Administration (FDA) granted accelerated...
4.
Luo F, Arter Z
Lung Cancer (Auckl)
. 2024 Nov;
15:161-167.
PMID: 39502188
Kirsten rat sarcoma viral oncogene homolog -mutant non-small cell lung carcinoma (NSCLC) accounts for approximately 10-13% of advanced nonsquamous NSCLC cases in Western populations, presenting a significant therapeutic challenge owing...
5.
Shim J, Kim Y, Yuh T, Lee J, Kim H, Hong M, et al.
Lung Cancer (Auckl)
. 2024 Nov;
15:149-159.
PMID: 39494146
Purpose: Small-cell lung cancer (SCLC) accounts for approximately 10-15% of all lung cancers and is characterized by a high recurrence rate, early metastasis, and poor prognosis. Before the FDA approved...
6.
Gupta B, Gosa Barrett L, Liu S
Lung Cancer (Auckl)
. 2024 Oct;
15:143-148.
PMID: 39376790
Fusions in neuregulin 1 () are rare oncogenic drivers that occur across a number of tumor types, including non-small cell lung cancer (NSCLC). has an EGF-like domain that serves as...
7.
Arter Z, Nagasaka M
Lung Cancer (Auckl)
. 2024 Sep;
15:129-133.
PMID: 39224878
On April 18, 2024, the Food and Drug Administration approved alectinib as an adjuvant treatment for patients with anaplastic lymphoma kinase ()-positive non-small cell lung cancer (NSCLC) after tumor resection....
8.
Liu Q, Zhang J, Wei M, Zhou X, Sun H, Dong Y, et al.
Lung Cancer (Auckl)
. 2024 Sep;
15:135-142.
PMID: 39224877
Background: Pulmonary spindle cell carcinoma (PSCC), a highly malignant tumor, often exhibits cell pleomorphism, a histopathological characteristic. Owing to its extremely low incidence, atypical imaging and clinical presentations, and insufficient...
9.
Zhu J, Chen J, Liu W, Zhang J, Gu Y
Lung Cancer (Auckl)
. 2024 Sep;
15:123-128.
PMID: 39221108
Mesenchymal-epithelial transition () gene has been identified as a promising target for treatments. However, different sites of the mutation show different effects to MET inhibition. Here, we reported a non-small...
10.
Arter Z, Nagasaka M
Lung Cancer (Auckl)
. 2024 Jul;
15:115-121.
PMID: 39011085
On December 22, 2023, the US Food and Drug Administration (FDA) approved the biologics license application for patritumab deruxtecan (HER3-DXd) for priority review. This treatment is aimed at adult patients...